RO WORKS WITH LILLY TO STREAMLINE PATIENT ACCESS TO AUTHENTIC ZEPBOUND(R) SINGLE-DOSE VIALS BY INTEGRATING WITH LILLY'S PHARMACY CHANNEL
Ro today announced it is working with Eli Lilly and Company to streamline access to Zepbound(R) (tirzepatide) single-dose vials for Ro patients with obesity. The vials will be available as a treatment option with an on-label prescription from a Ro-affiliated provider via an integration with the LillyDirect(R) self-pay pharmacy channel.